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doi:10.1016/j.clim.2007.07.018Abstract Plasmacytoid dendritic cells (pDC) represent the main source of interferon-α, a
cytokine with antitumor activity. However, in vitro studies point to pDC as a key subset for
induction of tolerance. Herein, we investigated pDC in sentinel lymph nodes (SLN) of melanoma
patients. We report that pDC were constantly found in SLN and represented, with Langerhans
cells, the most frequent dendritic cell subset. Their frequency in positive (with metastasis) SLN
was significantly higher than in negative (without metastasis) SLN. PDC were observed in the T
cell-rich areas of lymph nodes, particularly around high endothelial venules and, in metastatic
nodes, they accumulated in close vicinity with melanoma nests. Finally, pDC capability to
produce interferon-α in situ was impaired. Consistently, pDC expressed CD86, but neither CD80
nor CD83, suggesting a not complete activation in melanoma-draining lymph nodes. These results
are consistent with the hypothesis of a tolerogenic role played by pDC in tumor immunology.
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Dendritic cells (DC) are highly specialized antigen presenting
cells essential to generate primary immune responses [1]. It is
now clear that DC are not an unique homogeneous cell
population, but rather a pool of subsets with different origins,
phenotypes and functions [2–5]. However, two are the most
important DC subsets: myeloid DC and plasmacytoid DC
(pDC), the latter considered to be of lymphoid origin [2–5].
Myeloid DC reside in immature state in peripheral tissues
where actively capture and process antigens. Following
exposure to pro-inflammatory cytokines or pathogen-derived
products they undergo a maturation process and migrate via
the afferent lymphatics to the draining local lymph nodes [6].
Awell knownmyeloid DC subset is represented by Langerhans
cells (LC) which are located in the epidermis and character-
ized by the expression of CD1a molecules and Langerin [7]. In
contrast to myeloid DC, pDC do not reside in peripheral
tissues during homeostasis, but are encountered in the
peripheral blood and lymphoid organs [8–12]. The hallmark
of pDC is their unique capability to produce large amount of
interferon-α and -β (Type I IFN) in response to viruses [12,13].
Furthermore, pDC can differentiate into mature DC when
stimulated by viruses [8–10,12]. For these reasons pDC
represent key effectors in innate immunity and the ideal
cell population in connecting innate and adaptive immunity.
PDC are rarely detected in healthy lymph nodes, in
contrast they are abundant in inflamed lymph nodes where
they migrate through the high endothelial venules [13,14].
The sentinel lymph node (SLN) represents the first node on
the lymphatic draining way from a tumor and corresponds to
the preferential site of early metastasis [15]. Similarly,
primary immune responses against tumors are expected to
occur first in the SLN, where DC present tumor antigens to
naive T cells generating tumor-specific cytotoxic and/or
helper Tcell [16]. However, there is evidence showing that DC
have phenotypic and functional defects in the SLN of cancer
patients [17–19]. These studies analyzed classical myeloid
DC, but the role of pDC in the SLN remains to be assessed.
Indeed it seems that pDC may be of some relevance in human
tumor immunity and in particular in melanoma immune
responses: pDC have been recently described as an important
component of the lymphoid infiltrate in primary and
metastatic melanoma lesions [20] and a role of these cells
in priming naive melanoma specific CD8+ Tcells as well as in
IFN-α/β production has been described [20,21].
Myeloid DC subsets and pDC can now be traced by the
expression of specific molecules [4,5]. Taking advantage of
these tools, we sought to analyze the DC repertoire within
SLN of melanoma patients focusing on the presence and
function of pDC with the aim to investigate whether pDC play
a role in immune response to melanoma in vivo.Material and methods
Patients and human samples
Melanoma patients undergoing wide local excision of the
primary lesion plus sentinel node biopsy and patients under-
going complete regional lymphadenectomy for clinically
evident lymph node metastasis were enrolled in the studyafter obtaining informed written consents. The study was
conducted according to the Declaration of Helsinky Principles
and the Institutional Ethics Committee approved all des-
cribed studies. In total we have investigated n=39 SLN from
n=27 patients and n=9 clinically metastatic LN from n=9
patients. SLN was detected and excised as previously
described [22]. Briefly, all patients underwent pre-operative
lymphoscintigraphy using 99mTc-labelled nanocolloid albu-
min (Nycomed, Amersham, Sorin, Milan, Italy), performing
early dynamic and static views. pre-operative perilesional
intradermal injections of 0.5–1 ml of blue dye (Patent Blue V
2.5%, Laboratoire Guebert, Aulnay-Sous-Bois, France) were
performed 15–30 min before surgery. All blue nodes and
radioactive nodes with an in vivo- or ex vivo-background
count ratio of 2:1 or more were removed using gamma probe
(ScintiProbe MR 100, Pol.Hi.Technologies, Rome, Italy). For
research purposes SLN processing was performed as pre-
viously described with minor modifications [23]. Briefly, SLN
was bisected crosswise and one cutting surface was scraped 5
times with a scalpel blade by the pathologists. The cells were
collected in a 15 ml tube by rinsing the blade with phosphate
buffered saline (PBS-EuroClone, Whetherby, UK). Cells were
centrifuged and the pellet was re-suspended several times
vigorously in 1 ml of complete medium and then passed
through a cell strainer (70 μm pore diameter; BD Falcon, BD
Biosciences, Bedford, MA, USA) in order to remove fragments
and end up with a single cell suspension. SLN were processed
for routine histology with hematoxylin and eosin and
immunohistochemistry [22]. The immunohistochemical
study was performed using the peroxidase-antiperoxidase
immune complex method andmonoclonal antibodies for S100
protein (clone 4C4.9) and for anti-melanosome (clone
HMB-45); the reaction product was visualized by 3,3′
diaminobenzidine (DAB) chromogen, weakly counterstained
with hematoxylin, washed and mounted with Permount
media. All material was from Ventana, Tucson, AZ. Befory
surgery, 30 ml of blood was collected from each patients.
PBMCwere isolated from blood by Lymphoprep™ (Axis-Shield,
Oslo, Norway) gradient.
Reagents and antibodies for flow cytometry
Complete medium was prepared using RPMI 1640 (EuroClone)
supplemented with 1% penicillin/streptomycin (EuroClone),
2% glutamine (Sigma-Aldrich, Irvine, UK), 1% sodium pyr-
uvate and 10% heat inactivated FCS (EuroClone). The
following unconjugated or FITC-, or PE-, or PE-Cy5 con-
jugated mouse anti human monoclonal antibodies were used:
anti CD4 (SK3, IgG1), anti CD11c (S-HCL-3, IgG2b), anti CD36
(CB38-NL07-, IgM ), anti CD80 (L307.4, IgG1), anti CD83
(HB15e, IgG1), anti CD86 (2331 FUN-1, IgG1), anti HLA-DR
(L243, IgG2a), and anti-Lineage Cocktail 1(lin-1) from Becton
Dickinson (San Josè, CA); anti CD14 (M5E2, IgG2a) and anti
CD123 (9F5, IgG1) from BD-Pharmingen (San Diego, USA).
Anti BDCA1(AD5-8E7, IgG2a), anti BDCA2 (AC144, IgG1) and
anti BDCA3 (AD5-14H12, IgG1), from Miltenyi Biotec (Ber-
gisch Gladbach, Germany). Anti MxA mAb was kindly
provided by J. Pavlovic (Department of Virology, University
of Zurich, Switzerland). Anti CD1a (BL6, IgG1) and anti CD207
(Langerin, DCGM4,IgG1) were from Immunotech (Marseille,
France). All mAb dilutions and washing steps were done in
PBS containing 2% FCS and 2 mM EDTA. IsotyPE-matched Ab
186 G. Gerlini et al.were used as negative control. Cells were acquired using
FACSort and the CellQuest softwer (Becton Dickinson
Immunocytometry Systems, San Jose, CA).
Cell sorting and cultures
PDC cells were isolated by direct magnetic labeling with
BDCA2 conjugated-beads (Miltenyi Biotec) followed by
enrichment of labeled cells using a high-gradient magnetic
cell sorting device (Mini-MACS; Miltenyi Biotec). Cells were
then spun down on cytospins and stained with Giemsa. For
activation experiments, blood pDC were sorted by BDCA4
conjugated-beads (BDCA2 was not used because its binding
has been shown to inhibit IFN-α production [4]) and cultured
at a concentration of 1×104 cells/ml for 24 hours in presence
of IL-3 (R and D Sistems, Inc. Minneapolis, USA) and 5 hemag-
glutinating units /ml influenza (virus strain PR8). After
24 hours activated cells were processed for flow cytometry
studies, and IFN-α production was measured by ELISA in the
supernatant (R and D Sistems, Inc). In order to measure IFN-α
production from fresh SLN we cultured the entire SLN cell
suspension in presence of IL-3 without virus stimulation (the
number of pDC purified from SLN is too low to perform direct
measurements).Immunohistochemistry and immunofluorescence
Representative serial sections from paraffin embedded SLN
(n = 5 negative, n = 5 positive) and clinically metastatic nodes
(n = 5) were stained with anti CD123 mAb in order to localize
pDC within lymph nodes. CD123 stains also classical myeloid
DC and macrophages, although less strongly, but pDC were
distinguishable as CD123 positive cells with plasmacytoid
shape. Anti BDCA2 mAb was not used because is not suitable
for paraffin embedded tissues.
Sections were immunohistochemically studied using the
peroxidase-antiperoxidase immune complex method; the
reaction product was visualized by DAB chromogen, weakly
counterstained with hematoxylin, washed and mounted with
Permount media (Ventana).
Immunofluorescence studies were performed on frozen
sections from negative SLN (n=19), positive SLN (n=5),
clinically metastatic nodes (n=5). Sections were mounted on
slides, air-dried at room temperature, fixed in acetone for
10 minute and stored at –20 °C. Before staining slides were
pre-incubated 1 h with PBS/Triton X-100 0.3% containing
20 mg/ml bovine serum albumin. Sections were stained with
anti BDCA2 PE (Miltenyi Biotec) anti CD3 APC (IgG1, UCHT1,
BD PharMingen), and anti CD19 FITC (IgG1, HD37, Chemicon
Europe, Hampshire, UK), for 2 h to study localization of pDC
within the SLN. Fluorescein signal was amplified with anti-
FITC Alexa Fluor 488 conjugated (Molecular Probes Invitro-
gen, Milan, Italy) for 1 h. To study type I IFN production in
situ, sections were stained with anti MxA mAb for 2 h, then
slides were washed extensively with PBS and a subsequent
incubation (1 h) with a PE-conjugated secondary antibody
allowed visualization of the binding. A subsequent incubation
(2 h) with a FITC-conjugated anti BDCA2 mAb was performed
for double labeling. Frozen sections from varicella skin
lesions (n=5) were used as positive control for MxA staining.
Specificity of immune detection was established by omissionof the primary antibody. Sections were observed with a Leica
DM-IRBE confocal microsopy (Leica, Glattbrugg, Switzer-
land). PDC express MxA [24], thus, in case of type I IFN
secretion by pDC, the neighboring cells would also stain
positive for MxA [25]. Therefore we would have a subset of
MxA+ BDCA2+ cells representing pDC and a subset expressing
only MxA representing the neighboring cells. To quantify type
I IFN production by pDC in situ, the numbers of MxA and
BCDA2 positive cells was assessed on recorded digital images
calculating the mean values of cell numbers counted in three
different fields (magnification x400). Thereafter, the ratio
between MxA and BDCA2 positive cells was calculated to
correct for the density of infiltrating pDC and to make
possible comparison with varicella skin lesions.
Statistical analysis
Among SLN, pair wise frequency differences between 4 DC
subsets (BDCA1, 2, 3 and LC) were assessed using the
Wilcoxon non parametric test for matched samples. The
same test was used to assess pair wise frequency differences
between 3 DC subsets (BDCA1, 2, 3) for blood samples. In
order to take into account the multiple comparison problem
we fixed type I error at 0.008 and 0.017, respectively.
Among SLN and blood samples, for each of the 4 DC subsets
(BDCA1, 2, 3 and LC), the Kruskal-Wallis non parametric
analysis of variance was used to test the null hypothesis of no
distribution differences among positive SLN, negative SLN
and clinically metastatic nodes; the pair wise comparison of
this group were performed with the Mann-Whitney non para-
metric test for unmatched samples setting at 0.017 type I
error. The Kruskal-Wallis non parametric analysis of variance
was also used to test the null hypothesis of no distribution
differences for the ratio between MxA and BDCA2+ cells
among positive SLN, negative SLN, clinicallymetastatic nodes
and varicella skin lesions; the pair wise comparison of this
group were performed with the Mann-Whitney non para-
metric test for unmatched samples setting at 0.008 type I
error.
All tests were two-sided. All the analyses were performed
using Stata Statistical Software: Release 9.
Results
Identification of plasmacytoid dendritic cells in
sentinel node of melanoma patients
To assess the presence of pDC in sentinel lymph node of
melanoma patients, we performed flow cytometry analysis
on single cell suspension using anti BDCA2 - an antibody
specific for human pDC – and anti CD123. A BDCA2+ CD123+
cell population was detected in all the n=39 samples studied
(Fig. 1a). Further analysis showed that BDCA2+ pDC expressed
CD4, CD45 RA (Fig. 1b), HLA-DR , CD36 but did not express
CD11c (data not shown), corresponding to the typical pDC
immunophenotype [13]. Forward and side scattered proper-
ties of SLN pDC were similar to those of blood pDC being
located between lymphocytes and monocytes (data not
shown). Isolated pDC exhibited a plasmacytoid, roundish
morphology without dendritic processes (Fig. 1c). Similarly,
in situ pDC, detected as CD123+cells in paraffin embedded
Figure 1 Plasmacytoid dendritic cells characterization in sentinel lymph nodes of melanoma patients. (a-b) Single cell suspension
was triple stained with anti-BDCA2 / CD123 and CD4 or CD45RA and analyzed by flow cytometry. a) A BDCA2/CD123 double positive
population was observed. b) Gating in R1 plasmacytoid dendritic cells resulted positive for CD4 and CD45RA. c) BDCA2 positive cells
were sorted by magnetic beads, cytocentrifuged and stained with Giemsa (Original magnification x400). d) Immunohistochemical
staining with mAb anti-CD123 on paraffin embedded SLN of melanoma patients revealed the presence of roundish, plasmacytoid
CD123+ cells (Original magnification x400). e) Frozen sections of SLN were triple stained with anti-CD19 to identify B cells (green),
anti-CD3 to identify Tcells (blue) and anti-BDCA2 to identify pDC (red) and analyzed by confocal laser scanning microscopy. pDC were
exclusively localized within the T-cells area (Original magnification x200).
187Plasmacytoid dendritic cells in melanoma sentinel lymph nodessections (Fig. 1d) and as BDCA2+ cells in frozen sections (Fig.
1e), showed a roundish, typical plasmacytoid feature and
were observed within the T cell-rich area of LN (Fig. 1e).
Frequency of dendritic cell subsets in sentinel
nodes of melanoma patients
Using the BDCA1, 2, 3 antibodies we investigated the
presence of the different DC subsets in SLN of melanoma
patients. Since these nodes drain lymph from the skin we also
investigated LC by the expression of Langerin. As shown in
Fig. 2, LC and BDCA2+ pDC were the most frequent DC type
with median values of 0.50% (interquartile range: 0.32%–
0.77%) and 0.37% (interquartile range: 0.24%–0.56%) of total
SLN cells respectively (Wilcoxon test p value=0.073). Lower
frequencies (Wilcoxon test p valuesb0.008) were observed
for BDCA1+(median 0.29%; interquartile range: 0.15%–
0.47%) and BDCA3+ DC (median 0.14%; interquartile range:0.09%–0.20%) (Fig. 2b). In contrast, blood DC subsets
frequency in melanoma patients were different (Wilcoxon
test p valuesb0.017) with higher frequency observed for
BDCA1+ cells (median 0.56%; interquartile range: 0.41%–
0.65%), followed by BDCA2+ cells (median 0.33%; interquar-
tile range: 0.21%–0.48%) and BDCA3+ cells (median 0.08%;
interquartile range: 0.05%–0.10%) while LC were not
detected (Fig. 2b). Mean values were not statistically
different from those observed in blood of normal donors
(BDCA1+ cells: 0.55±0.17%, BDCA2+ cells 0.43±0.14% and
BDCA3+ cells 0.11±0.05% - data not shown).Plasmacytoid dendritic cells accumulation in
metastatic lymph nodes
Among the SLN (n=39) from melanoma patients (n=27)
melanoma cells were found in 8 SLN. In all cases, metastatic
Figure 2 Plasmacytoid dendritic cells represent a major DC subset in sentinel lymph nodes of melanoma patients. Dendritic cells
subsets were identified by flow cytometry analysis using mAb anti-BDCA1, -BDCA2 and -BDCA3. Langerhans cells were identified by the
expression of the specific marker Langerin. Since BDCA1 is also expressed by some B lymphocytes, DC were identified by the expression
of BDCA1 and the negativity for the lineage markers (Lin-1). a) A representative flow cytometry analysis is shown. The numbers
represent the percentage of cells within the total cell population. b) Quantification of dendritic cell subsets in sentinel lymph nodes
and blood from multiple donors. Horizontal bars represent the median.
Figure 3 Plasmacytoid dendritic cells accumulation in meta-
static lymph nodes of melanoma patients. a) BDCA2+ pDC
identified by flow cytometry analysis in negative sentinel lymph
nodes (n=31), metastatic sentinel lymph nodes (n=8) and
clinically metastatic lymph nodes (Mtx) (n=9). * indicate a
statistically significant difference between the groups. Hor-
izontal bars represent the median. b) Dot plot of flow cytometry
analysis showing the highest number of BDCA2/HLA-DR double
positive pDC within one of the clinically metastatic lymph node.
188 G. Gerlini et al.lesions were micrometastases (clinically unapparent and
detected in sentinel lymph nodes, as defined in the
American Joint Commettee of Melanoma Staging Cancer
System) [26]. The frequency of pDC in positive SLN (median
0.84%; interquartile range: 0.46%–1.18%) was significantly
higher (Mann-Whitney test p value=0.006) than in negative
SLN (median 0.34%; interquartile range: 0.21%–0.47%) (Fig.
3a). Interestingly, the higher percentage of pDC was
observed in the SLN with the larger metastasis. This data
suggested that the frequency of pDC may be related to the
presence of melanoma cells in the SLN. To address this
question we further extended our investigation to mela-
noma patients with clinically evident metastatic LN under-
going total local lymphanedectomy. In metastatic LN the
presence of pDC was slightly higher (median 0.90%;
interquartile range: 0.70%–1.30%) than that observed in
positive SLN although the increase was not statistically
significant (Mann-Whitney test p value=0.596) (Fig. 3a).
Notably, in one case it reached up the percentage of 6.1
(Figs. 3a and b).
Plasmacytoid dendritic cell distribution within
metastatic lymph node
As described above, the highest percentages of pDC were
found within metastatic LN, raising the question of whether
melanoma cells may somehow enhance pDC migration in the
LN. Therefore, the localization within the LN and their
position respect to melanoma cells was studied by immuno-
histochemistry on paraffin embedded sections stained with
anti CD123 mAb. PDC appeared as aggregates of numerous
cells in close vicinity with melanoma nests (Figs. 4a and d)
Figure 4 Plasmacytoid dendritic cells aggregate around melanoma cells in metastatic lymph nodes. Representative sections of
positive sentinel lymph nodes and clinically metastatic lymph nodes were stained with mAb anti-CD123. a, c and d) Clusters of
plasmacytoid dendritic cells around melanoma cells. b) A massive infiltration of plasmacytoid dendritic in a clinically metastatic
lymph node. c and d) Plasmacytoid dendritic cells distribution around high endothelial venules. e) A large melanoma metastasis with a
thin rim of lymph node. f) High magnification of the inset in e showing a high number of plasmacytoid dendritic cells. Black arrows
indicate clusters of plasmacytoid dendritic cells and red arrow indicate single pDC within the melanoma mass. Melanoma cells are
indicated by M and asterisks indicate high endothelial venules. a-c and f (Original magnification x200), d (x300), e (x100).
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metastatic LN (Fig. 4b). Melanoma cells-pDC contact was a
frequent finding at the edge of the tumor mass (Figs. 4a
and d), while pDC within the melanoma mass were observed
only occasionally (Fig. 4c, indicated by the red arrow). PDC,
within the Tcell-rich areas of LN, were observed around high
endothelial venules (HEV) which also stained positive (Figs.
4c and d, indicated by the asterisks). PDC were frequently
detected between HEV and melanoma cells (Figs. 4c and d)
suggesting a migration from blood towards the tumor area. In
a case of clinically metastatic lymph node we detect a very
low percentage of pDC by flow cytometry (0.05%), indeed,
histopathological examination of that case showed that the
lymph node was almost completely replaced by melanoma
cells, remaining only a thin peripheral rim of lymph node
tissue (Fig. 4e), where a high number of CD123+ pDC were
observed (Fig. 4f).Type I interferon production by Plasmacytoid
dendritic cells in sentinel lymph node
The main feature of pDC is the capability to produce type I
IFN upon virus stimulation and there is evidence that even
cancer cells may trigger a such production [27]. Further-
more, freshly isolated pDC from ovarian carcinomas express
MxA [24], a type I IFN–inducible intracellular protein well
established as a surrogate marker for local type I IFN
production [25]. Therefore we asked whether pDC were
able to secrete type I IFN in SLN and in clinically metastatic
LN of melanoma patients. To assess this functional aspect we
performed a double labeling on frozen sections of LN with
anti MxA and anti BDCA2 mAbs. In case of type I IFN secretion
by pDC, the neighboring cells, beyond pDC themselves,
would stain positive for MxA [25]. Indeed, MxA expression
was mostly limited to the BDCA2+ cells (Fig. 5a) and only a
Figure 5 Type I IFN production and activation profile of
Plasmacytoid dendritic cells a) SLN sections were stained with
anti-BDCA2 and anti-MxA mAb and analyzed by fluorescence
microscopy: MxA expression was limited to the BDCA2+ cells. b)
Type I IFN production by pDC in negative SLN (n=19), in positive
SLN (n=5), in clinically metastatic LN (Mtx LN) (n=5) and in
varicella lesions (n=5), was assessed counting the numbers of
MxA+ cells and BCDA2+ cells and calculating the mean values of
cell numbers in three different fields (magnification, x400).
Thereafter, the ratio between MxA+ and BDCA2+ cells was
calculated to correct for the density of infiltrating pDC and to
make possible comparison among the different conditions.
Horizontal bars represent the median. * indicate a statistically
significant difference between varicella and the melanoma
groups. c) Representative data of flow cytometry analysis of
CD80, CD83 and CD86 on fresh pDC from blood and SLN and on
influenza virus-activated pDC derived from the same melanoma
patient. Influenza virus-activated pDC expressed all themarkers,
while fresh pDC from SLN and blood expressed respectively high
and moderate levels of CD86 molecules. Filled histograms
represent isotype control. Data are representative of six
independent experiments.
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detected around BDCA2 and MxA double positive cells (data
not shown). These findings suggested that pDC in SLNproduce low amount of type I IFN. To quantify this production
in situ, the total numbers of MxA+ cells and BDCA2+ cells
were counted. To correct for the density of infiltrating pDC,
the ratio between MxA+ and BDCA2+ cells were calculated
for each samples and compared with those obtained in
varicella, a condition characterized by a strong type I IFN
production by infiltrating pDC [28]. While the differences in
the values of Mxa/BDCA2 ratios among the LN groups did not
reach the level of statistical significance (Kruskall-Wallis
p-value=0.419) (negative SLN: median 1.10%; interquartile
range: 0.90%–1.80%; positive SLN: median 1.80%; interquar-
tile range: 1.10%– 2.00%; clinically metastatic LN: median
1.50%; interquartile range: 1.20%; 2.00%), those obtained in
varicella skin lesions were significantly much higher (median
8.20%; interquartile range: 7.70%– 8.60%; Mann-Whitnet test
p-valuesb0.008) meaning that type I IFN production in LN is
poor (Fig. 5b). Consistently, IFN-α was not detected in
supernatant from fresh LN cell suspension as revealed by
Elisa (data not shown).
Immunophenotype of Plasmacytoid dendritic cells
in sentinel lymph node
The ability to produce type I IFN by pDC is directly related to
their activation state [29]. In order to study this aspect we
analyzed the expression of the costimulatory molecules
CD80, CD86 and the maturation marker CD83 in blood and
SLN pDC aswell as in influenza virus-activated pDC. Blood pDC
were negative for CD80 and CD83, while expressed low levels
of CD86 molecules. Similarly, in both positive (n=2) and
negative (n=4) SLN pDC did not expressed CD80 and CD83 but
showed an upregulation of CD86. In contrast, influenza virus-
activated pDC expressed all these markers (Fig. 5c). These
findings suggest that pDC are only partially activated in SLN
and are consistent with the low ability to produce type I IFN
observed in situ.
Discussion
PDC are considered a key defensive mechanism of the innate
immune system, crucial to limit viral infections spreading
thanks to the capability to produce large amount of type I IFN
[2,9,10,28]. Since type I IFN inhibit proliferation of certain
tumors, their role has also been studied in the immune
response to cancer cells [20,24,30–35].
Herein, we have identified pDC as an important DC subset
localized in the SLN of melanoma patients. We have
demonstrated that pDC are present in higher percentage in
positive SLN than in negative SLN. Additionally, we have
observed that pDC frequency was even higher in clinically
metastatic nodes. It's worth to mention that pDC are rarely
detected in normal lymph nodes, while they accumulate in
certain inflammatory LN conditions [13,14,36,37]. As
described in inflamed LN, pDC were often observed around
high endothelial venules suggesting that they migrate from
the blood. In certain pathological conditions characterized
by accumulation of pDC in the lesions, i.e. psoriasis,
systemic lupus erythematosus and varicella infection, the
numbers of circulating pDC are decreased [28,29,38], in
contrast, in melanoma patients the percentages of pDC in
the blood were comparable with those observed in healthy
191Plasmacytoid dendritic cells in melanoma sentinel lymph nodesdonors, indicating that pDC recruitment in SLN may occur
gradually in the time.
The presence of a high number of pDC in melanoma
bearing lymph nodes suggests that pDC may be recruited
within the lymph nodes by the presence of melanoma cells or
by soluble factors secreted by the tumor. Consistent with this
hypothesis, a high number of pDC were found around mela-
noma metastasis as observed by immunohistochemical
analysis. Furthermore, it has been shown that melanoma-
secreted cytokines are widely detected in melanoma SLN
[39]. This could explain why pDC are observed even in SLN
devoid ofmelanoma cells, but draining lymph from cutaneous
melanoma areas. A factor that can mediate a specific
recruitment of pDC, as shown in ovarian carcinomas
[20,24], is the Stromal Derived Factor (SDF)-1 which is largely
produced by melanoma cells [20]. Notably, in the studies
describing pDC in solid cancers, these cells have been often
described in close vicinity with neoplastic cells, as we found
in SLN with metastasis [20,24,40]. It could be hypothesized
that the few resident pDC, after interaction with dangerous
signals, in this case represented by a neoplastic process, start
to produce inflammatory chemokines, the so called CXCR3
ligands, promoting the recruitment of circulating pDC at sites
of constitutive SDF-1 expression as described in viral
infections [41,42]. Notably, SDF-1 is widely expressed in LN,
particularly on HEV [41]. Thereafter, the pDC positioning
within the lymph node may be further re-directed by
melanoma derived-SDF-1, thus explaining the cluster forma-
tion around tumor nests.
The role of pDC in the immune response in oncology is still
largely controversial. Some findings suggest that pDC may
have a potential role in inducing active immunity, but on the
other hand a growing body of evidence strongly propose a
tolerance role for these cells. Indeed, pDC may limit the
tumor spreading by type I IFN, awell known cytokinewith anti
tumor properties andwith immune regulatory functions. Type
I IFN can protect CD8+ T-cells from antigen-induced cell death
[43] and can promote final maturation of myeloid DC [44].
However, the capability to produce type I IFN in our study was
rather poor. This was observed by direct measurements of
IFN-α in the fresh SLN cell suspension (data not shown) and by
the finding that a very few cells, apart pDC, expressed MxA
protein, in contrast to varicella lesions where a diffuse MxA
expression was observed. It has been shown that pDC in-
filtrating psoriatic lesions express CD80, CD83 and high levels
of CD86 consistent with the idea of an in situ activation. In
line with the activation profile, psoriatic pDC expressed large
amount of IFN-α [29,38]. In contrast, we have found that pDC
in SLN did not express neither CD80 nor CD83, but only CD86
suggesting a defective in situ activation. This was in
accordance with the low ability to produce type I IFN
observed in situ. The scattered MxA single positive cell
sporadically found in this study might be due to a certain
moderate production of type I IFN in basic conditions or, in the
context of a mild inflammatory process in SLN. These findings
suggest that pDC, although unable to produce constitutively
type I IFN in SLN, might still be stimulated in certain
conditions such as the presence of inflammatory cytokines.
This phenomenon, however, does not seem to be specifically
melanoma-related as demonstrated by the fact that no
significant differences in MxA expression were found in
negative SLN, positive SLN and in metastatic LN. Further-more, in vitro experiments, with stimulation of pDC by
melanoma cell lines, did not show any type I IFN secretion
(data not shown). However, we cannot rule out the possibility
that some melanoma cells in vivo, or stimulation with fresh
melanoma cells in vitro, might induce type I IFN production
by pDC. In previous study on solid tumors, type I IFN
production by pDC has been described to be totally absent
in breast cancer [40], moderate in primary melanoma [20]
and very high in malignant ascites of ovarian carcinomas
patients [24]. In favor of a positive role played by pDC in anti
cancer immunity is the report showing that, in vitro, pDC can
prime naive CD8+ T-cell specific for melan-A antigen to
become IFN-gamma secreting cells [21].
In strong contrast, a series of data depict pDC as negative
regulators of tumor immunity. In this regard it has been
shown that infiltration of pDC in primary breast tumor
correlates with an adverse outcome suggesting a role of pDC
in the progression of cancer cells [40]. Negative effects have
also been reported in ovarian carcinomas, where a high
number of functionally defective pDC are described in
malignant ascites, in the solid tumor and in the tumor
draining LN [24]. Additionally, pDC can polarize T-cell
response toward a Th2 profile [45], an immune response
favoring the tolerance towards tumor. Furthermore pDC can
generate CD8 T-regulatory cells which produce IL-10 [46], a
strong immune suppressive cytokine, produced also by
melanoma cells, capable of inhibiting the antigen presenting
capacity of DC [47,48] and to induce anergy in melanoma
specific CD8 T cells [49].
In conclusion, SLN of melanoma patients comprise
different subsets of DC including pDC. PDC number is higher
in melanoma bearing LN and, in situ, they are localized
around melanoma cells, suggesting a specific recruitment.
Several additional data are needed in order to uncover the
role exerted by pDC in tumor immunity, however the findings
of this study, together with the above mentioned observa-
tions in other tumors, are consistent with a role for pDC in
cancer immunological tolerance.
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